"The current system is not working. We need a system where the state takes greater responsibility," said Minister of Social Affairs Jakob Forssmed (KD).
According to him, today's system is complicated and difficult to understand for companies that want to introduce new medicines in Sweden.
This, in turn, determines Swedish patients' access to various medicines and treatments.
The Dental and Pharmaceutical Benefits Agency decides which medicines are included in high-cost coverage. The regions decide which new medicines are used in their hospitals. In addition, the regions have a joint council, the NT Council, which issues recommendations.
The investigator will be Karin Johansson. She will complete the proposal by the end of December 2027.
